Navigation Links
NovaQuest Advances 'Virtual Development' Model With Strategic Investment in TOPIGEN Pharmaceuticals
Date:8/27/2007

RESEARCH TRIANGLE PARK, N.C., Aug. 27 /PRNewswire/ -- NovaQuest has made a strategic investment in TOPIGEN Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company specializing in respiratory disorders. The investment was part of a private placement of C$26 million (US$25 million) in the Montreal-based company.

Last week's The investment by NovaQuest, the strategic partnering group of Quintiles Transnational, helps TOPIGEN accelerate its Phase II lead-product clinical programs. NovaQuest and Quintiles first provided strategic product development advice to TOPIGEN three years ago; the relationship has since evolved into an integrated development partnership.

Patricia Lamothe, TOPIGEN's Chief Financial Officer, said: "The ability to access NovaQuest's clinical expertise and Quintiles' development capabilities is a tremendous benefit to our company as we continue to advance our product candidates for significant breakthroughs in the treatment of respiratory diseases."

NovaQuest Vice President Ben Cons, Ph.D., said: "Having been very active in 2006, with 16 strategic investments, our focus now is to create fewer but larger partnerships. We're seeking high potential biotechs -- those with excellent pipelines and strong management teams. Our managed partnership with TOPIGEN is an example of this.

"We believe that NovaQuest's strong clinical experience and intellectual capital, backed by Quintiles' global development resources, is a great fit to help TOPIGEN advance its clinical candidates efficiently and strategically."

In November NovaQuest made a strategic investment in Canadian biotech company BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis. For all of 2006, NovaQuest participated as a minority investor in funding rounds that raised a total of $342 million for 16 emerging biotechnology companies worldwide.

NovaQuest, the strategic partnering group of Quintiles Transnational, is an industry pioneer in offering tailored financial and operational solutions that help pharmaceutical and biotech companies overcome development and commercialization challenges, including leveraging "virtual clinical development" models. Its unique managed-partnership approach ensures sponsorship by senior-level executives; access to global development and commercial resources and expertise; and efficient operational delivery of services. Since 2000, NovaQuest partnerships have committed more than $2 billion in capital to pharmaceutical and biotech companies of all sizes. For more information, please visit http://www.novaquest.com.

Quintiles Transnational Corp. is powering the next generation of healthcare by providing a broad range of professional services in drug development, financial partnering and commercialization for the pharmaceutical, biotechnology and healthcare industries. With 19,000 employees and offices in more than 50 countries, it is focused on providing customer- centric solutions that are the gold standard of the industry. For more information, please visit the company's Web site at http://www.qtrn.com.


'/>"/>
SOURCE NovaQuest
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. The Affymetrix GeneChip Scanner 3000 New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range
2. Quintessence Biosciences advances cancer drug
3. Healthcare slow to adopt genetic advances
4. Wireless advances in Madison, heats up in Waukesha
5. GE Healthcares CT Scanner advances coronary imaging
6. Cancer treatment advances as trials show no harm to mice
7. New CT scanner by GE Healthcare advances imaging technology
8. Small wonders: Intersection of biotech and nanotech will produce big advances
9. Standards Needed for Advances in Healthcare Technology
10. Virtual communities make online connections
11. Virtual-reality welding simulator an opportunity for Chippewa Valley college
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced ... this eBook by providing practical tips, tools, and strategies for clinical researchers. , ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... YM (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. ... microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory and ...
Breaking Biology Technology:
(Date:6/21/2016)... Columbia , June 21, 2016 ... to the new role of principal product architect ... named the director of customer development. Both will ... chief technical officer. The moves reflect NuData,s strategic ... in response to high customer demand and customer ...
(Date:6/16/2016)... 2016 The global ... reach USD 1.83 billion by 2024, according to ... Technological proliferation and increasing demand in commercial buildings, ... drive the market growth.      (Logo: ... development of advanced multimodal techniques for biometric authentication ...
(Date:6/9/2016)... , June 9, 2016  Perkotek an innovation leader in attendance control systems ... seamlessly log work hours, for employers to make sure the right employees are actually ... http://photos.prnewswire.com/prnh/20160609/377486LOGO ... ... ...
Breaking Biology News(10 mins):